Search
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPhenindione
go.drugbank.com/drugs/DB00498ApprovedInvestigationalAn indandione that has been used as an anticoagulant. Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects.
DS-2325a
go.drugbank.com/drugs/DB18134InvestigationalDS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Recombinant Cholera Toxin B Subunit
go.drugbank.com/drugs/DB11643ApprovedInvestigationalRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
Iothalamic acid
go.drugbank.com/drugs/DB09133ApprovedIothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Synonyms: 1-deoxy-1-(methylamino)-D-glucitol 5-acetamido-2,4,6 triiodo-N-methylisophthalamateACA 125
go.drugbank.com/drugs/DB05489InvestigationalAn IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. … ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
Pranlukast
go.drugbank.com/drugs/DB01411InvestigationalIt antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InhibitorsMelaleuca alternifolia leaf
go.drugbank.com/drugs/DB14372InvestigationalIt is not an approved drug.
Mixtures: Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampooNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … In addition, nirsevimab was developed as a single-dose treatment for all infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an RSV season.
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates